Trial Search Results

Pilot Indocyanine Green Imaging for Mapping of Arm Draining Lymphatics & Nodes in Breast Cancer

The purpose of this study is to determine if Indocyanine Green (IC-GREEN) is comparable to isosulfan blue (IS-BLUE) in the identification of arm lymphatics and arm-draining nodes during nodal staging procedures in breast cancer.

Stanford is currently not accepting patients for this trial.

Lead Sponsor:

Stanford University

Stanford Investigator(s):


  • Device: SPY Elite Imaging
  • Drug: Indocyanine Green
  • Drug: Isosulfan blue
  • Drug: 99technetium-sulfur colloid radiolabel


Phase 2


Inclusion Criteria:

   - Ability to understand and the willingness to sign a written informed consent document.

   - Signed written informed consent.

   - Women undergoing sentinel lymph node biopsy.

   - Women with breast cancer with known or suspected lymph node involvement.

   - Women undergoing sentinel node identification and completion axillary lymph node

   - Women of 18 years of age or older.

   - Eastern Cooperative Oncology Group (ECOG) or Karnofsky Performance Status 0,1,2.

   - Complete Blood Count (CBC) and basic Metabolic Panel within 6 months

Exclusion Criteria:

   - History of liver or kidney failure will not be eligible.

   - Allergies to iodine containing products will not be eligible.

   - Women who are pregnant will not be eligible.

   - Psychiatric or addictive disorders or other conditions that, in the opinion of the
   investigator, would preclude the patient from meeting the study requirements.

Ages Eligible for Study

18 Years - 90 Years

Genders Eligible for Study


Not currently accepting new patients for this trial

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Shannon Meyer